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Abstract: Tuberculosis (TB) is the leading cause of death from a single infectious microorganism
and Bacillus Calmette Guerin (BCG), the only authorized vaccine, does not confer protection against
pulmonary TB. Based on the hypothesis that mucosal protection could help to prevent the infection
at the site of entrance, the objective of this work was to develop an intranasal vaccine against
Mycobacterium tuberculosis (Mtb), the microorganism that causes TB. Our approach consisted of
the use of polymeric nanocapsules (NCs) with an oily core and a polymer shell made of chitosan
(CS) or inulin/polyarginine (INU/pArg). The immunostimulant Imiquimod, a Toll-like receptor-7
(TLR-7) agonist, was encapsulated in the oily core and a fusion protein, formed by two antigens
of Mtb, was absorbed either onto the NC surface (CS:Ag and INU:pArg:Ag) or between two
polymer layers (INU:Ag:pArg) in order to assess the influence of the antigen positioning on the
immune response. Although CS NCs were more immunostimulant than the INU/pArg NCs in vitro,
the in vivo experiments showed that INU:pArg:Ag NCs were the only prototype inducing an adequate
immunoglobulin A (IgA) response. Moreover, a previous immunization with BCG increased the
immune response for CS NCs but, conversely, decreased for INU/pArg NCs. Further optimization of
the antigen and the vaccination regime could provide an efficacious vaccine, using the INU:pArg:Ag
NC prototype as nanocarrier.
Keywords: 6 kDa early secretory antigenic target (ESAT-6); 10 kDa culture filtrate protein (CFP-10);
vaccination; Imiquimod; Toll-like receptor-7 (TLR-7); antibodies; cytokines; complement system;
reactive oxygen species (ROS)
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1. Introduction
The use of vaccines to prevent severe infectious diseases has been a historical landmark in medicine.
However, some pathogens remain elusive to the development of an efficient vaccine against them, such
as the case of tuberculosis (TB), the most deadly infectious disease in the world, caused by Mycobacterium
tuberculosis (Mtb) [1]. The BCG vaccine, containing the Bacillus Calmette Guerin, which is the only
one licensed to date for TB, protects against non-pulmonary TB in infants, however, it is unreliable
in protecting against pulmonary TB, which accounts for most of the disease burden worldwide [2].
Approved vaccines based on live-attenuated or inactivated pathogens provide a good immunogenicity
in general, but the risk associated to their administration is relevant. For that reason, subunit vaccines
are preferred due to their inherent safety, although they show limited immunogenicity [3]. Moreover,
the adjuvants available on the market, mainly based on aluminum salts, have failed to induce an
efficient immune response against some antigens, due to a biased or a suppressive immune response,
among other factors [4].
For these reasons, new strategies to stimulate the immune system towards better protective
responses are strongly needed. In this sense, nanotechnology offers the possibility to develop more
powerful vaccines. This is because the association of antigens to nanocarriers enables their protection
against degradation and improves their presentation to the immune system [5,6].
Polymer- and lipid-based nanocarriers are among the most widely used nanocarriers for vaccine
development due to, among other properties, the ir biocompatibility and biodegradability, the capacity
of some polymers and lipids to interact with pattern-recognition receptors (PRRs) or cell membranes,
and their capacity to enhance both humoral and cellular immune responses [5,7–10]. In particular,
polymeric nanocapsules (NCs) have been shown to be promising carriers for the delivery of a variety
of antigens against different pathogens [11–13].
In most vaccines, a balanced type 1 T helper / type 2 T helper (Th1/Th2) response is desired to trigger
a wide-ranging immune response and, consequently, protective efficacy [8,14]. The immunogenicity of
the nanosystems can be further enhanced by including small immunostimulant molecules in the particle
structure [4]. In this sense, Imiquimod (IMQ) has been described as a good modulator of the innate
immunity and activator of the Th1 immune response via binding to the Toll-like receptor-7 (TLR-7) on
antigen presenting cells (APCs). Previous work from our laboratory has shown that encapsulation
of IMQ in chitosan (CS) NCs induced protective antibody levels against the recombinant hepatitis B
surface antigen (HB) in mice immunized by the intranasal (i.n.) route [8]. Interestingly, the i.n. route
could also induce additional protection at the mucosal level, with the production of immunoglobulin
isotype A (IgA) antibodies and activation of local immune cells [15]. Prompt, appropriate mucosal
immune responses could be very helpful to neutralize pathogens at their main route of entrance, such
as in the case of Mtb, avoiding the development of the infection altogether.
Having this background in mind, the goal of this work was to develop polymeric NCs containing
the immunostimulant IMQ and a fusion protein antigen of the 6 kilodaltons (kDa) early secretory
antigenic target (ESAT-6) and the 10 kDa Culture Filtrate Protein (CFP-10) against Mtb to be administered
intranasally. To study the effect of the polymeric shell and antigen distribution on the immunogenicity
of an i.n. vaccine, we selected two different NCs. CS and inulin/polyarginine (INU/pArg) were selected
as polymeric shell for the first and second NC prototypes, respectively. Moreover, in the INU/pArg NCs,
the antigen was added on the surface of the pArg polymer shell or between the two polymer layers to
assess the influence of the antigen positioning on the immune response. In fact, the entrapment of the
antigen in a bilayer disposition of polymeric NCs has recently been shown to offer adequate protection
and an enhanced immune response towards the associated antigen [11].
The biocompatibility and the immunostimulant properties of the NCs were tested in vitro with
different cell lines and human peripheral blood mononuclear cells (PBMCs). Finally, the immunogenicity
of the vaccine prototypes by the i.n. route was tested either in naïve mice or in mice previously
immunized (subcutaneously, s.c.) with the BCG vaccine, to test the synergy between the conventional
BCG vaccine and the polymeric NC vaccines.
Pharmaceutics 2020, 12, 489 3 of 22
2. Materials and Methods
2.1. Materials for the Synthesis of the Nanocapsules (NCs)
Ultrapure CS hydrochloride salt (CS.HCl) (Molecular weight (Mw) 42.7 kilodaltons (kDa),
deacetylation degree of 88%) was purchased from Heppe Medical Chitosan GmbH (Saale, Germany).
Inutec®SL1 (25% modified inulin (INU) suspension in glycerol) was a kind gift from CreaChem
(Tienen, Belgium).
PArg (Mw 24 kDa) was purchased from PTS (Valencia, Spain) and Imiquimod was provided by
Ferrer HealthTech (Barcelona, Spain).
Sodium glycocholate and sodium cholate were purchased from Dextra (Reading, UK).
Miglyol® 812 was donated by Cremer Oleo GmbH & Co (Hamburg, Germany) and linoleic acid
was provided by Acros Organics, Thermo Fisher (Waltham, MA, USA).
The 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol) 1000]
(18:O PE-PEG1000) was purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA).
Sucrose and trehalose were purchased from Acofarma (Madrid, Spain).
ESAT-6/CFP-10 fusion protein (ECH) was provided by Lionex Gmbh (Braunschweig, Germany,
www.lionex.de).
All solvents employed were of analytical grade and supplied by Merck Organic solvents
(Madrid, Spain). Endotoxin-free water was collected in a Millipore Ultrapure Water System equipped
with a filter unit for endotoxin removal.
2.2. Nanocapsules’ Synthesis and Characterization
The NCs were synthetized by the solvent-displacement method, as described previously [16,17].
For CS NCs, the organic phase was prepared with 125 µL of a mixture of linoleic acid an Miglyol®
812 (9.5:3, v/v ratio) and 1 mg of IMQ, 20 mg of the PEGylated phosphoethanolamine 18:0 PE-PEG1000
and 25 µL of an aqueous solution of 200 mg/mL sodium cholate in 5 mL of ethanol. The aqueous
phase contained 5 mg of CS.HCl salt dissolved in 10 mL of water. After pouring the organic phase
over the aqueous phases, stirring the suspension and evaporating the organic solvent in a rotavapor
(Büchi, Switzerland), the suspension was taken to a final volume of 5 mL with ultrapure water.
For the INU/pArg NCs, the organic phase was formed by 34.5 µL of a mixture of linoleic acid and
Miglyol® 812 (6.5:1, v/v ratio) and 1 mg of IMQ, 5 mL of ethanol, and 25 µL of an aqueous solution of
sodium glycocholate at 200 mg/mL. The aqueous phase was prepared by dissolving 15 mg of Inutec
SL1 in 10 mL of water. The NCs were prepared as described above for the CS NCs. Afterwards, 0.5 mL
of a pArg aqueous solution at 10 mg/mL was added to the INU NCs, before or after the addition of
the antigen, to form the INU:pArg:Ag and the INU:Ag:pArg NCs, respectively. The formulation was
shaken for 1 h at 300 rpm in a thermoblock (Eppendorf Thermomixer R) to allow the adsorption of the
positively charged pArg over the negatively charged INU core by electrostatic interactions.
Lyophilization studies of the final NC prototypes were performed in the presence of 5 and 10%
sucrose or trehalose, as cryoprotectant.
Particle size and polydispersity index (PdI) of the formulations in ultrapure water were
characterized by photon correlation spectroscopy in a Zetasizer Nano-S (Malvern Instruments;
Malvern, UK) at 25 ◦C. Zeta potential (Z-potential) was also measured in the same equipment by laser
Doppler anemometry (LDA) using an appropriate cell and 1 mM KCl as solvent.
The IMQ encapsulated in the oily core was determined after ultracentrifugation (30,000 rpm, 1 h,
15 ◦C) of the NCs to separate the undernatant, containing the free IMQ (Cf), from the cream, with
the encapsulated IMQ (Ce). Besides, total IMQ concentration (Ct) was also measured in initial NCs.
All samples were diluted 1:10 with MeOH to break the NCs and solubilize the IMQ. Subsequently,
the samples were analyzed by HPLC, as described in [8]. A calibration curve was also made up with
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standard solutions of IMQ to determine the concentration in each sample. The encapsulation efficiency
(%EE) and the drug loading (%DL) were quantified directly according to the formula:
%EE = (Ce/Ct) × 100, %DL = [IMQ (mg)/NCs (mg)] × 100 (1)
2.3. Adsorption of the Antigen onto the Nanocapsules and Quantification of the Adsorbed Protein
For the development of the model vaccine, a preliminary screening was performed, adding
the ECH fusion protein to the NCs at different ratios (polymer:antigen, w/w), to find the maximum
antigen loading which did not compromise the NCs colloidal stability. The antigen was added to
the IMQ-loaded NCs and the mixture was incubated at room temperature with constant orbital
shaking (300 rpm) for one hour in a thermoshaker (Eppendorf Thermomixer R) to allow the protein
adsorption to the polymer surface. The amount of antigen adsorbed on the surface of IMQ-loaded NCs
(CS:Ag and INU:pArg:Ag) or entrapped between two polymer layers (INU:Ag:pArg) was determined
by SDS-PAGE and Coomassie blue staining. The NCs were ultracentrifuged (30,000 rpm, 1 h, 15 ◦C) to
separate free (ECHf) from attached protein (ECH.NCs) and an aliquot of both fractions was loaded in a
10% polyacrylamide gel. A molecular marker was also loaded in a different lane to follow the protein
separation and to check the ECH protein molecular weight. After running the electrophoresis, the gel
was stained and the density of the protein bands was quantified in a ChemiDoc equipment using
the LabImage software (Bio-Rad Laboratories, Inc, Hercules, CA, USA). The percentage of absorbed
antigen (%AA) was calculated according to the formula:
%AA = ECH.NCs/(ECH.NCs + ECHf) (2)
2.4. Materials for Protein, Cell, and Animal Studies
ESAT-6 and CFP-10 antigens were provided by Lionex Gmbh (Braunschweig, Germany,
www.lionex.de).
Mouse monoclonal antibody (mAb) against human complement factor C3 and the split protein
C3b (C3-C3b) was from Abcam, (Cambridge, UK) and polyclonal goat anti-mouse IgG antibodies (Abs)
conjugated with alkaline phosphatase (AP) were from Dako (Glostrup, Denmark).
The 5-bromo-4-chloro-3-indolyl-phosphate (BCIP)/nitro blue tetrazolium (NBT) substrate
solution, 2′,7′-dichlorodihydrofluorescindiacetate (H2DCFDA), anti-mouse IgA, anti-mouse IgG,
and o-phenylenediamine dihydrochloride (OPD) substrate were purchased from Sigma-Aldrich Co.
and molecular weight marker was from Thermo Fisher Scientific, Spain.
Cell Titer 96® AQueous One Solution Cell Proliferation Assay kit, 3-(4, 5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), and endotoxin test were from
Promega Biotech Ibérica, (Madrid, Spain) and Associates of Cape Cod, Inc. (Falmouth, MA, USA),
respectively.
Phorbol 12-myristate-13-acetate (PMA) was from Abcam (Cambrige, UK), lipopolysaccharide
(LPS) from InvivoGen (Toulouse, France), and phytohaemagglutinin (PHA) from Sigma-Aldrich Co.
The MILLIPLEX® MAP Kit used for cytokine profile characterization was provided by Millipore,
Merck KGaA (Darmstadt, Germany).
2.5. Cells and Culture Conditions
Five different cell lines from the American Type Culture Collection (ATCC) (Manassas, VA, USA)
were used: Raw 264.7 (mouse macrophages), THP-1 (human monocytes), A549 and NCI-H460 (human
lung epithelial cells), and HL-60 (human promyeloblast cells).
The cells were cultured in Roswell Park Memorial Institute medium (RPMI) supplemented with
10% (v/v) heated, inactivated fetal bovine serum (FBS) (PAA; Pasching, Austria), 2 mM glutamine and
100 U/mL of penicillin/streptomycin, at 37 ◦C in 5% CO2 atmosphere. Cells were diluted every two or
three days, after reaching a 70–80% of confluence.
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2.6. Evaluation of Bacterial or Endotoxin Contamination
The absence of bacterial contamination was evaluated by seeding 100 µL of the samples on
Luria-Bertani (LB) agar plates under aseptic conditions. The plates were incubated at 37 ◦C for 24–72 h.
Potential endotoxin contamination on the NC formulations was also assessed by the gel-clot assay,
following the manufacturer’s instructions.
2.7. Toxicity Studies on Macrophages and Lung Epithelial Cells
Cell viability tests were performed in two macrophage (RAW 264.7 and PMA-differentiated
THP-1) and two lung epithelial (A549 and NCI-H460) cell lines.
The colorimetric MTS test was used to quantify the changes on cell viability after 24 h of incubation
with different concentrations of the IMQ-loaded NCs.
The cells were seeded on 96-well plates at a density of 1.5 × 104 cells/well for THP-1 and RAW264.7,
and 6 × 103 and 7 × 103 cells/well for A549 and NCI-H460, respectively. THP-1 cells were incubated
with phorbol 12-myristate-13-acetate (PMA) at 10 ng/mL for 24 h to induce their differentiation into
macrophages. The medium with PMA was replaced with fresh medium before adding the NCs.
The maximum concentration tested for CS and INU/pArg NCs was 1440 and 545 µg/mL, respectively.
Several dilutions (1:2) of each NC prototype were also tested in order to determine the half-maximun
inhibitory concentration (IC50). Culture medium alone and with NCs was used for background
subtraction and to discard any interference of the NCs in the absorbance. The percentage of cell
viability was calculated using the following Equation:
%Cell viability = [(Abs Cells&NCs − Abs NCs)/(Abs Cell − Abs Medium)] × 100 (3)
2.8. Production of Reactive Oxygen Species (ROS)
For the characterization of ROS release, the promyeloblast cell line HL-60 was used. The cells
were seeded at a density of 1 × 105 cells/well in a 96-well plate and incubated with the NCs during 1, 3,
6, and 14 h. The NCs were tested at three different concentrations (50, 100, and 200 µg/mL for CS NCs
and 10, 50, and 100 µg/mL for INU:pArg NCs).
PMA at 20 µM was added to the cells as positive control and cells incubated only with culture
medium were used as negative control. After the corresponding incubation time, H2DCFDA at 2.5 µM
was added to the cells and incubated for 30 min at 37 ◦C. After diffusion into the cell and oxidation
to 2′,7′-dichlorofluorescein (DCF) by ROS in a concentration-dependent rate, the cells were washed
and the fluorescence produced by DCF was measured in a Beckman Coulter FC500 flow cytometer
(Beckman Coulter, IN, USA). Cells were also labelled with propidium iodide (PI) to discriminate live
and dead populations.
2.9. Analysis of Complement Activation
Complement activation induced by the IMQ-loaded NCs in a pool of plasma from healthy donors
was assessed by measuring the degradation of the C3 factor by Western blot.
Equal volumes of plasma, PBS, and samples were mixed and incubated at 37 ◦C for 1 h. Zymosan
at a final concentration of 1 mg/mL and PBS were used as positive and negative controls, respectively.
The NCs were tested at three different concentrations (50, 100, and 200 µg/mL for CS NCs and 10, 50,
and 100 µg/mL for INU/pArg NCs).
After incubation, supernatants were collected and 2 µL were mixed with sample buffer and loaded
onto a 10% SDS-PAGE gel and transferred to a Polyvinylidene Difluoride (PVDF) membrane using the
Transblot Semidry Transfer Equipment (Bio-Rad Laboratories, Inc).
The PVDF membranes were blocked with 5% nonfat milk in Tris-buffered saline in Tween 20
(TBS-T), and incubated sequentially with mouse monoclonal antibody (mAb) against human C3-C3b
followed by polyclonal goat anti-mouse IgG antibodies (Abs) conjugated with alkaline phosphatase
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(AP), both diluted 1:2000 in 5% nonfat milk in TBS-T. Each incubation was carried out for 1 h at
room temperature and the membranes were washed three times with TBS-T between each incubation.
The bands of the intact and split C3 protein were visualized adding a BCIP/NBT substrate solution
that reacted with the AP and formed a dark precipitate. The intensity of the bands was quantified
on the ChemiDoc (Bio-Rad Laboratories, Inc). The ratio of split/intact protein was normalized to the
negative control.
2.10. Cytokine Profile Evaluation
Cytokines’ release was studied in human PBMCs from three healthy donors. The PBMCs were
obtained from whole blood by density gradient centrifugation. After centrifugation, cells were washed
with PBS and seeded at a density of 1.75 × 106 cells/mL in 96-well U-bottom plates. The cells were
allowed to rest for 24 h in the incubator before adding the samples.
The NCs were added at the same final concentrations as in the previous experiment and the
plate was incubated for another 24 h. As positive control, lipopolysaccharide (LPS) at 1 µg/mL with
phytohaemagglutinin (PHA) at 10 µg/mL was used and cells without any treatment were used as
negative control.
After incubation with the NCs, the plate was centrifuged at 1200 rpm for 5 min and 100 µL of
supernatant per well were recovered and stored at −80 ◦C until measurement.
A MILLIPLEX® MAP Kit for 11 cytokines (granulocyte monocyte-colony stimulating factor
(GM-CSF), interferon (IFN)-γ, interleukin (IL)-10, IL-12, IL-17, IL-1β, IL-2, IL-4, IL-5, IL-6, and
tumor necrosis factor (TNF)-α was used to measure the concentration of these cytokines in the
supernatants collected from the PBMCs using a MAGPIX® instrument (Millipore, Merck KGaA,
Darmstadt, Germany) and following the manufacturer’s instructions. The MAGPIX® software was
used for the analysis of the standard curves and the samples.
Mouse IFN-γ, TNF-α, and IL-17 release by the splenocytes of immunized animals after antigen
recall was monitored by enzyme-linked immunosorbent assay (ELISA) (Invitrogen 88-7314-86,
88-7324-77, 88-7371-77, ThermoFisher Scientific, Loughborough, UK).
2.11. Immunization Experiments
Female C57BL/6 mice were obtained from Charles River, UK, and were between 8 and 12 weeks
of age before experimental use. In the groups specified, mice were subcutaneously immunized with
5 × 105 CFU BCG Pasteur (100 µL) or vehicle control. After 12 weeks, intranasal booster immunizations
were given consisting of 3x IMQ-loaded polymeric NCs coated with 10 µg ECH in 50 µL per animal per
dose, or vehicle control. Doses were given 2 weeks apart. These immunizations were performed under
light anesthesia. Three weeks following the final immunization, animals were culled by intraperitoneal
(i.p.) administration of 200 mg/kg pentobarbitone solution (Pentoject®, Animalcare Ltd., York, UK).
Bronchoalveolar fluid was collected by passing 1 mL of PBS into the lungs using a 22-gauge catheter
positioned in the trachea.
2.12. Detection of Specific Antibodies
Antibody levels were quantified by ELISA. Antigens [ECH, ESAT-6, and CFP-10] were coated
onto a plate at 2 µg/mL overnight, followed by blocking for 2 h with PBS containing 1% bovine serum
albumin (BSA). Serum samples were loaded at a 1:10 dilution in PBS with 1% BSA and 4-fold serial
dilutions were made. Bronchoalveolar lavage fluid (BAL) samples were loaded undiluted and 3-fold
serial dilutions were performed. All samples were incubated on the plate in triplicate for 1 h at 37 ◦C.
Levels of IgA (BAL) or IgG (serum) were detected using peroxidase-conjugated anti-mouse IgA or
anti-mouse IgG and OPD substrate. Plates were read on a Tecan Infinite F200 Pro plate-reader at
450-nm absorbance.
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2.13. Statistical Analysis
The GraphPad Prism 8 software (GraphPad Software Inc., San Jose, CA, USA) was used for data
representation and statistical analysis. Each experiment was performed at least three times (n ≥ 3) and
the results of the different assays were represented as mean ± standard deviation (SD). T-student or
Mann–Whitney test was performed to determine significant differences between negative control and
treatments. In the graphs, results are indicated as: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.
3. Results
3.1. Physicochemical Characterization and Stability of the Nanocapsules
During this work, three different vaccine prototypes of polymeric NCs were developed. For the
first prototype, CS was used as a polymer shell because of the good biocompatibility and the proven
capacity of CS-based nanocarriers to elicit mucosal and systemic immune response against a variety of
antigens after i.n. administration [8,18–20]. The oily core consisted of a mixture of linoleic acid and
Miglyol® 812. PEGylated phosphoethanolamine 18:0 and sodium cholate were used as surfactant
and as co-surfactant, respectively. The antigen was absorbed onto the surface by incubating the
antigen solution with the preformed NCs. The adsorption was probably caused by a combination of
electrostatic and hydrophobic interactions (Figure 1 and Table 1).
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against the Mycobacterium tuberculosis fusion protein ESAT-6/CFP-10 (ECH protein). In the oily core,
Imiquimod, a TLR-7 agonist, was added as adjuvant to increase the immunogenicity of the fusion
protein. Ag: Antigen, CS: Chitosan, INU: Inulin, pArg: Polyarginine, TLR-7: Toll-like receptor-7.
Table 1. Chemical composition of the CS and INU/pArg nanocapsules (NCs) developed in this work.
CS: Chitosan, INU: Inulin, pArg: Polyarginine.
Chemical Composition CS NCs INU/pArg NCs
Oil Miglyol/linoleic acid Miglyol/linoleic acid/glycerin
Adjuvant Imiquim d
Polymer Chitosan
Modified inulinSurfactant 18:0 PE-PEG1000
Co-surfactant Sodium cholate Sodium glycocholate
Second polymeric shell - Polyarginine
Antigen disposition Surface Surface/Polymer bilayer
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For the second prototype, pArg was selected as a polymer shell due to the penetrating properties
of this polypeptide, which could help crossing the mucosal barrier [21]. In the pArg NCs, a first
layer of hydrophobized INU and sodium glycocholate were used to increase the stability of the
naoemulsion (NE), whose core was again a mixture of linoleic acid and Miglyol® 812. Afterwards,
antigen was adsorbed onto the pArg surface. However, the antigen could also be added at the
surface of the INU before adding the pArg shell, entrapping it in a sandwich-like arrangement [11].
This engineering strategy allowed obtaining two different vaccine prototypes, one with the antigen
adsorbed on the surface (INU:pArg:Ag) and another one with the antigen protected by a polymeric
bilayer (INU:Ag:pArg) (Figure 1 and Table 1), which can influence the vaccine performance, the reason
why we considered it interesting to be studied [11].
To enhance the immunostimulatory properties of the NCs, IMQ, a lipophilic immunostimulant,
was incorporated in the oily core of the nanosystems. The IMQ-loaded polymeric NCs, both for CS
and pArg prototypes, had a particle size about 150 nm and a PdI lower than 0.2 (Table 2). The surface
charge was positive for CS and INU/pArg NCs and negative for INU NCs (Table 2), consistent with the
positive charge of CS and pArg polymers and the negative charge of the cholate-stabilized INU NCs.
Table 2. Physicochemical characterization, Imiquimod encapsulation efficiency, and antigen absorption
of the different nanocapsules’ prototypes.
Nanocapsules Size (nm) Z (mV) IMQ %EE %AA
CS 145 ± 14 +28 ± 4.5 60 ± 4 n.a.
CS:Ag 152 ± 15 +8 ± 10 n.a. 60 ± 6
INU 158 ± 7 −37 ± 4 69 ± 6 n.a.
INU:Ag 136 ± 7 −36 ± 6 - n.d.
INU/pArg 158 ± 22 +20 ± 1 - n.a.
INU:Ag:pArg 151 ± 11 +27 ± 8 - 55 ± 5
INU:pArg:Ag 158 ± 12 +31 ± 7 - 30 ± 10
IMQ EE: Imiquimod encapsulation efficiency, AA: Antigen absorbed on the NCs. Polydispersity index (PdI) ≤ 0.2
in all the size measurements; n.a.: Not applicable; n.d.: Not determined. Ag: Antigen, CS: Chitosan, INU: Inulin,
pArg: Polyarginine.
The selected antigen was a fusion protein of two Mtb antigens, ESAT-6 and CFP-10, named ECH
protein, with a molecular weight of approximately 21.5 kDa and a theoretical isoelectric point (pI) of
5.06. ESAT-6 and CFP-10 are virulence-related Mtb proteins which are absent in the BCG vaccine [22].
The polymer: antigen ratio 1:0.2 (w/w) was selected as the best ratio for both, CS and pArg NCs,
based on the SDS-PAGE and dynamic light scattering (DLS) studies (data not shown). The %AA
was estimated by SDS-PAGE (Table 2) and was about 60, 55, and 30% for CS:Ag, INU:Ag:pArg, and
INU:pArg:Ag NCs, which corresponded to an antigen loading of 0.4, 1.1, and 0.55%, respectively.
The free antigen that was not bound to the NCs allowed an initial burst release that could boost
the immune response [23]. For that reason, free antigen was not removed from the suspension and,
for immunization studies, the amount of antigen injected was calculated according to the initial
protein concentration.
The percentage of IMQ in the NCs was measured by HPLC (as described in Section 2.2) and
similar encapsulation efficiency was found for CS and INU/pArg NCs (Table 2). The encapsulation
efficiency was about 60–70% in both cases, which corresponded with a drug loading of 4.2% for CS
NCs and 13% for INU/pArg NCs, respectively.
The nonloaded CS NCs were stable in suspension at 4 ◦C for at least 6 weeks, as shown by
the size and Z-potential measurements (Figure 2). However, the antigen-loaded NCs were stable
only one week (Supplementary Figure S1) due to, likely, the neutralization of the CS NCs’ surface
charge after addition of the ECH fusion protein (Table 2). For this reason, for all the experiments
with antigen-adsorbed CS NCs, the antigen was added in situ and incubated one hour before the
administration of the formulation.
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Figure 2. i ( r ), PdI, and Zeta-potential (lines and symbols) of Imiquimod-loaded CS (A,B),
INU:Ag:pArg and INU:pArg:Ag (C,D) anocapsules stor d at 4 ◦C at different tim points. Due to the
reduced stability of the CS nanocapsules after antigen adsorption (Figure S1), the nanocapsules were
tested in the absence of the antigen. Size and PdI were measured in ultrapure water and Zeta-potential
in 1 mM KCl. Ag: Antigen, CS: Chitosan, INU: Inulin, pArg: Polyarginine.
The INU/pArg NCs, both with the antigen protected by the pArg shell (INU:Ag:pArg) or with
the antigen on the surface (INU:pArg:Ag), were stable for three weeks at 4 ◦C (Figure 2). After this
period, the NCs showed a tendency to undergo coalescence (data not shown). To increase their stability,
the antigen-loaded CS and INU/pArg NCs were lyophilized with 5 or 10% sucrose or trehalose as
cryoprotectant. Among all of them, the use of 10% sucrose proved to be effective to preserve the
INU/pArg NCs during the lyophilization process and further reconstitution in water, but not for the
CS:Ag NCs (Supplementary Figure S2). The lyophilized INU/pArg NCs were easily reconstituted by
adding water and immediately vortexing the vial for two minutes. After reconstitution, the lyophilized
NCs showed a size, a PdI, and a Zeta-potential similar to the values observed after their lyophilization.
Oppositely, the size and PdI of the CS:Ag NCs increased after the lyophilization, and the use of
trehalose or a lower sucrose percentage produced similar results (data not shown).
In order to be able to draw adequate conclusions from the in vitro experiments, the stability of
the NCs was tested in complete culture medium by recording size and PdI at 4 different time points
(Figure 3). CS:Ag and INU:Ag:pArg NCs were stable at all the time points recorded (4 h), whereas the
stability of INU:pArg:Ag NCs was limited to less than 30 min, but presumably long enough to allow
particle internalization and drainage to the lymph nodes, which usually takes place in the first minutes
after administration [24].
Hence, the protection of the antigen by the pArg shell increased the stability of the INU/pArg
NCs, in comparison with the adsorption of the antigen into the surface of the NCs, in physiological
medium. Conversely, CS NCs with the antigen on the surface were very stable.
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Figure 3. Stability of Imiquimod-loaded CS:Ag (A), INU:Ag:pArg, and INU:pArg:Ag (B) nanocapsules
on RPMI culture medium supplemented with 10% FBS and incubated at 37 ◦C. Graphs represent the
size (bars) and PdI (lines and symbols) vs. time of i cubation. Ag: Antigen, CS: Chitosan, FBS: fetal
bovine serum, INU: Inulin, pArg: Polyarginine.
3.2. Cytocompatibility of the Polymeric Nanocapsules in Different Cell Lines
The presence of endotoxin and bacterial contamination in the NCs was ruled out with an endotoxin
test and by seeding the NCs in LB agar plates, respectively, to avoid any wrong assignment of the
biological effects induced by bacterial contaminants to the NCs. The NCs were free of any source
of contamination.
Since the NCs were designed for intranasal administration, two macrophage (RAW 264.7,
PMA-differentiated THP-1) and two pulmonary epithelial (NCI-H460, A549) cell lines were used
to test their cytocompatibility, as representative cells that can be found in the mucosal epithelium
and respiratory tract. IMQ-loaded NCs were incubated at several concentrations with the cells to
check the cytocompatibility of the nanosystems. At concentrations lower than 100 µg/mL, the NCs
were cytocompatible with all the tested cells, except INU/pArg NCs with the pulmonary cells, which
showed a lower cytocompatibility (Figure 4). Among them, the macrophage-differentiated THP-1
showed the highest IC50 and A549 the lowest one (Table 3), indicating that pulmonary epithelial
cells are more sensitive to the NCs than macrophage cells. Regarding composition, CS NCs were
more cytocompatible in all cell lines in comparison with INU/pArg NCs, as shown in Figure 4 and
Table 3. In summary, CS and INU/pArg NCs were cytocompatible with all the cell lines tested at
low-intermediate concentrations, but they were toxic at high concentrations.
The increased toxicity of INU/pArg NCs in comparison with CS NCs must be related to their
composition and, specifically, the higher IMQ content (Table 3), because both NCs were positively
charged and they showed a similar size and Z-potential (Table 2).
Table 3. Half-maximum inhibitory concentration (IC50) values of IMQ-loaded CS and INU/pArg
nanocapsules in four different cell lines incubated with the nanocapsules for 24 h. The corresponding
IMQ concentration is also indicated. CS: Chitosan, IMQ: Imiquimod, INU: Inulin, pArg: Polyarginine.
Cell Line
IC50 (µg/mL)
CS INU/pArg
NCs IMQ NCs IMQ
RAW 264.7 455 2.96 117 2.05
THP-1 810 5.26 192 3.36
NCI H460 226 1.47 57 1.00
A549 197 1.28 31 0.54
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Figure 4. Percentage of cell viability of RAW 264.7, macrophage-differentiated THP-1, NCI-H460, and
A549 incubated with different concentrations of CS and INU/pArg nanocapsules for 24 h. CS: Chitosan,
INU: Inulin, pArg: Polyarginine. Statistical significance: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001,
**** P ≤ 0.0001.
3.3. Reactive Oxygen Species’ Release in HL-60 Cells upon Exposure to the Nanocapsules
ROS release is related with cell signaling, but also with cell toxicity when their concentration is
high [25]. However, at low concentration, ROS could help in antigen cross-presentation and stimulation
of Th1 immune responses, which could be a useful adjuvant mechanism to induce a cellular immune
response [26,27].
Pharmaceutics 2020, 12, 489 12 of 22
The human promyelocytic cell line, HL-60, was selected to measure NC-induced ROS release
because of the capacity of these cells to produce and modulate ROS in a dose-dependent manner [28,29].
The NCs were incubated with the cells at three different concentrations for short (1 and 3 h) and long
(6 and 14 h) periods. Due to the higher toxicity of INU/pArg NCs, the concentrations tested for this
prototype were 100, 50, and 10 µg/mL, while for CS NCs, concentrations were 200, 100, and 50 µg/mL.
After a short incubation time (Supplementary Figure S3), the NCs were not able to induce a significant
production of ROS at the concentrations tested. However, after incubation for 6 h, CS NCs induced low
ROS levels at a concentration of 200 µg/mL (Figure 5). After 14-h incubation time, CS induced ROS
release at concentrations of 50 µg/mL and 200 µg/mL, and INU/pArg NCs at 100 µg/mL, respectively
(Figure 5).
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induce activation of the complement system, possibly through the MB-lectin or alternative 
pathways, due to their polysaccharide composition.  
Figure 5. Reactive oxygen species (ROS) release in HL-60 cells incubated with CS and INU/pArg
nanocapsules at three different concentrations during 6 and 14 h. CS: Chitosan, INU: Inulin and pArg:
Polyarginine, PMA: Phorbol 12-myristate 13-acetate. Statistical significance: * P ≤ 0.05, ** P ≤ 0.01,
*** P ≤ 0.001.
Moreover, both types of NCs also induced ROS in the A549 pulmonary cell line at the highest
concentration tested after short incubation times (1 h and 3 h, Supplementary Figure S4), which could
be related with the higher toxicity of the NCs on these lung epithelial cells, in comparison with the
macrophage cell lines.
3.4. Complement Activation in Human Plasma Induced by the Polymeric Nanocapsules
The main role of the complement system is to eliminate pathogens, by opening pores on their
surfaces, but also to participate in the pathogen opsonization followed by phagocytosis and induce
a series of inflammatory mediators that help to fight infection [30]. These mediators enhance both
humoral (Th2) and cellular (Th1) immunity. For this reason, the activation of the complement system is
a crucial step on the innate and acquired immunity to fight against pathogens. In fact, in vitro activation
of this system, induced by nanostructure-based vaccines, has been correlated with a good immune
response in vivo [31,32]. Hence, degradation of the C3 factor, a common step in all the complement
activation pathways (mannose-binding-lectin, classical, and alternative pathways), was determined
by Western blot in a pool of plasma incubated with the NCs (Figure 6) [30]. Only CS NCs induced a
dose-dependent C3 protein degradation, which was statistically significant at 200 µg/mL and similar
to the one induced by the positive control (Zymosan at 1 mg/mL). Hence, CS NCs induce activation
of the complement system, possibly through the MB-lectin or alternative pathways, due to their
polysaccharide composition.
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Figure 6. Relative quantification of the C3 complement factor protein degradation induced by the
Imiquimod-loaded CS and INU/pArg nanocapsules at three different concentrations. CS: Chitosan,
INU: Inulin, pArg: Polyarginine. Statistical significance: * P ≤ 0.05.
3.5. Cytokine Release Induced by the Polymeric Nanocapsules
Some cytokines are able to polarize the activated T helper (Th) lymphocytes into a Th1 (cellular)
or Th2 (humoral) phenotype, or the macrophages into a M1 (pro-inflammatory) or M2 phenotype
(anti-inflammatory) [33].
The analysis of the cytokine profile induced after vaccination or infection is complex and, the refore,
it is difficult to predict the type of immune response that will be generated based only in this profile.
More ver, the evelopment of Th1 and Th2 effector lym hocytes will also depend on the antigenic
stimulation [34]. However, the re is a clear evidence that IFN-γ and/or IL-12 polarize Th cells towards
a Th1 profile, while IL-4 induces a Th2 phenotype [35]. Hence, a p nel of cytokines involved in Th1
(IL-2, IL-12p70, INF-γ, and TNF-α) and Th2 immune res onse (IL-4, IL-5, IL-6, and IL-10) were tested.
I additio , cytokines involved in inflammation, Th17 immune respons , and cell proliferation, such
as IL-1β, IL-17, and GM-CSF, respectiv ly, were also studied [36].
The polymeric NCs induced low levels of TNF-α, GM-CSF, IL-6, and IL-10 (Figure 7) and
undetectable or very low levels of all the other cytokines tested. CS NCs at 200 µg/mL produced the
highest concentrations but th difference with the negative control was not statistically signifi ant for
any of them.
3.6. Systemic Immune Response against the ESAT-6/CFP-10 Fusion Protein after Intranasal Immunization
with the Polymeric Nanocapsules
3.6.1. Characterization of Specific IgG and IgA Antibodies against ESAT-6/CFP-10
A preliminary experiment was carried out to test the immunogenicity of the NCs, alone or in
combination with the BCG vaccine. We selected a model vaccine against the ESAT-6 and CFP-10
antigens of Mtb, two early secreted antigens that are not present in the BCG vaccine, synthetized
as a fusion protein (ECH protein). Hence, immunization with this fusion protein, in combination
with the BCG vaccine, could induce specific humoral and cellular immune responses against Mtb to
complement the limited protection induced by the licensed vaccine.
It is worthwhile to mention that no relevant signs of toxicity, such as weight lost, impaired
breathing, or death, were detected in the animals vaccinated with any of the NC vaccine prototypes.
Moreover, no macroscopic changes were observed in any of the organs analyzed after the culling.
The humoral response against the individual antigens (ESAT-6 and CFP-10) was characterized in the
sera (IgG) and in the BAL (IgA) of animals immunized with the polymeric NCs by the i.n. route
and compared to the control group (PBS) and the group immunized subcutaneously with the BCG
vaccine (Figure 8). Specific IgG and IgA titers were determined by ELISA. The three NC prototypes
induced significant IgG titers against both antigens (except for INU:Ag:pArg against the ESAT-6
protein) compared to the BCG and the PBS group.
Pharmaceutics 2020, 12, 489 14 of 22
Regarding IgA titers, in general, the y were insignificant and only the INU:pArg:Ag prototype
induced specific IgA antibodies against the ESAT-6 antigen. Interestingly, for the CS:Ag NC prototype,
previous priming with the BCG vaccine induced similar or even higher antibody titers, but the contrary
was observed for both INU/pArg NC prototypes. In general, previous immunization with the BCG
vaccine reduced the antigenicity of the INU:pArg:Ag and INU:Ag:pArg prototypes (Figure 8).
Moreover, the prototype with the antigen on the surface (INU:pArg:Ag) induced higher antibody
levels against ESAT-6, both for IgG and IgA, than the prototype with the antigen protected by the
polymeric shell (INU:Ag:pArg).
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Figure 7. GM-CSF, TNF-α, IL-6, and IL-10 concentrations induced by Imiquimod-loaded CS and
INU/pArg nanocapsules in PBMCs from healthy donors after 24 h of incubation. PBS was used as
negative control and LPS+PHA as positive control. GM-CSF: granulocyte monocyte-colony stimulating
factor, TNF-α: tumor necrosis factor alpha, IL-6: interleukin 6, IL-10: interleukin 10, CS: Chitosan,
INU: Inulin, pArg: Polyarginine. Statistical significance: * P ≤ 0.05, *** P ≤ 0.001.
Pharmaceutics 2020, 12, 489 15 of 22
Pharmaceutics 2020, 12, x 15 of 22 
 
but the contrary was observed for both INU/pArg NC prototypes. In general, previous 
immunization with the BCG vaccine reduced the antigenicity of the INU:pArg:Ag and INU:Ag:pArg 
prototypes (Figure 8).  
 
Figure 8. Serum IgG (A) and IgA (B) titers against CFP-10 and ESAT-6 measured in sera and BAL 
diluted 1/10 and 1/3, respectively, after three intranasal immunizations with the CS:Ag, 
INU:pArg:Ag, and INU:Ag:pArg nanocapsules in naïve mice or in mice previously immunized 
subcutaneously with the BCG vaccine (+BCG). Mice treated with PBS (PBS) or only immunized with 
BCG (BCG) were used as control groups. Ag: Antigen, BAL: bronchoalveolar lavage fluid, CS: 
Chitosan, Immunoglobulin (Ig), INU: Inulin, pArg: Polyarginine. Statistical significance: * P ≤ 0.05, ** 
P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. 
Moreover, the prototype with the antigen on the surface (INU:pArg:Ag) induced higher 
antibody levels against ESAT-6, both for IgG and IgA, than the prototype with the antigen protected 
by the polymeric shell (INU:Ag:pArg).  
3.6.2. Characterization of the Cellular Immune Response in Splenocytes from Immunized Animals 
Apart from the humoral response, the nanovaccine prototypes were also tested for their 
capacity to induce a specific cellular immune response (Th1 or Th17). In fact, the IMQ adjuvant has 
been described to induce Th1 polarization through stimulation of the TLR-7 receptor [37]. 
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animals to measure IFN-γ, TNF-α, and IL-17 production, which are secreted from Th1 and Th17 
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Interestingly, only the ESAT-6 and the ECH fusion protein were able to induce IFN-γ and IL-17 
release in animals immunized with the CS and the INU/pArg prototypes (Figure 9). The antigen 
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Figure 8. Serum IgG (A) and IgA (B) titers against CFP-10 and ESAT-6 measured in sera and BAL
diluted 1/10 and 1/3, respectively, after three intranasal immunizations with the CS:Ag, INU:pArg:Ag,
and INU:Ag:pArg nanocapsules in naïve mice or in mice previously i unized subcutaneously with
the BCG vaccine (+BCG). Mice treated with PBS (PBS) or only immunized with BCG (BCG) were used
as control groups. Ag: Antigen, BAL: bronchoalveolar lavage fluid, CS: Chitosan, Immunoglobulin
(Ig), INU: Inulin, pArg: Polyarginine. Statistical significance: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001,
**** P ≤ 0.0001.
3.6.2. Characterization of the Cellular Immune Response in Splenocytes from Immunized Animals
Apart from the hum ral response, the n ovaccine prototypes were also tested for their capacity
to i duce a sp cific cellular immune response (Th1 or Th17). In fact, th IMQ adjuvant has b en
describ d to indu e Th1 polarization through stimulation of the TLR-7 receptor [37]. Accordingly,
an antigen recall experiment was carried out with splenocytes from immunized animals to measure
IFN-γ, TNF-α, and IL-17 production, which are secreted from Th1 and Th17 subsets. The splenocyte
were incubated with CFP-10, ESAT-6, or the ECH fusion protein, and the supernatants were collected
for cytokine measurement.
Interestingly, only the ESAT-6 and the ECH fusion protein were able to induce IFN-γ and IL-17
release in animals immunized with the CS and the INU/pArg prototypes (Figure 9). The antigen
recall induced the highest IFN-γ concentration in naïve animals immunized with the INU/pArg
prototypes and in animals immunized with the CS:Ag NCs, but previously primed with the BCG
vaccine. The same tendency was observed for IL-17, although the cytokine concentration was very low
in all the groups. In contrast, TNF-α was not detected in any of the groups tested (data not shown).
Hence, the polymeric NC vaccines were able to induce IFN-γ and IL-17 release, a Th1 and a Th17
activator of cytokines, respectively, but only against the ESAT-6 antigen. The CFP-10 antigen induced
only a weak production of IFN-γ in animals immunized with the INU:pArg:Ag NCs.
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4. Discussion
Three vaccine prototypes were designed and developed during this work, using CS or INU/pArg
NCs as antigen nanocarriers. IMQ was incorporated in the oily core as an additional adjuvant.
The IMQ-loaded CS:Ag, INU:pArg:Ag, and INU:Ag:pArg NCs showed a similar particle size of about
150 nm, appropriate for nasal administration. In this sense, for an efficient delivery through the
mucosal routes, it was stablished that the particle size should be smaller than the mucus mesh size [38].
This easily explains why NPs, in general, performed better than microparticles [39–43]. However,
in the nanometric range, in vivo data has shown that very small nanometric size (30 nm) may be
detrimental compared to larger ones (200 nm) [44]. Besides, not only the particle size, but also the
composition, play a critical role when using NPs for nasal administration. In 1998, Alonso’s group
reported the importance of PEG to increase the mucopermeation of polyester-based NPs [45], and, after
that, many other studies confirmed the importance of an adequate PEG coating to favor the diffusion
across the mucus layer [46,47].
On the other hand, the nanometric size of the developed NCs was also adequate to have a
preferential internalization by dendritic cells (DCs) [6,48]. DCs induce a better T-cell stimulation
than other APCs, such as macrophages and B-cells, and play a relevant role in pathogen capture and
induction of a primary immune response. For that reason, particle vaccines try to target these cells [49].
Moreover, the NCs had a low (CS:Ag) or high (INU:pArg:Ag and INU:Ag:pArg) positive charge, which
is also useful for the interaction with the negatively charged mucin following internalization in the
mucosa [47,50].
The selected antigen was a fusion protein (ECH) of two well-known Mtb antigens, ESAT-6 and
CFP-10. Both proteins belong to the region of difference (RD1) of Mtb, which is absent from all strains of
BCG and is related with the virulence of the Mtb and M. bovis strains. In fact, the ESAT-6/CFP-10 protein
complex could be related with macrophage apoptosis during TB infection [22]. The ECH recombinant
protein is a potent immune activator for both humoral and cellular immune responses. Moreover,
the i.n. administration of the recombinant protein in mice, in combination with and adjuvant, promoted
the cellular immune response in comparison with the s.c. or intramuscular (i.m.) immunization
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routes that induced higher antibody and lower cellular immune responses [51]. Besides, it has been
recently described that innate immune cells, monocytes/macrophages, and natural killer (NK) cells can
also be trained through vaccination, pathogen colonization, or even previous infections [52]. These
trained cells display stronger activation after a second exposure to the microbial molecules. Hence,
activation of a broad set of immune cells could be the key to fight those pathogens that have a complex
infection cycle.
Based on these results, the objective of this work was to investigate the potential of two different
polymeric NC, made of two cationic polymers, CS and pArg, as carriers for the i.n. delivery of the ECH
fusion protein, and if a previous boost with the BCG vaccine could improve the immune response by
training the innate immunity. To increase the adjuvancy of the NCs, IMQ, a TLR-7 binding agonist,
was encapsulated in the oily core of the NCs. The binding of this agonist to TLR-7 in APCs induces
the release of pro-inflammatory cytokines, such as IFN-α, TNF-α, and IL-12, which, in turn, promote
differentiation of immature Th cells into Th1 effector cells [37].
The release of TNF-α, IL-6, and IL-10 has been previously described for IMQ-loaded CS NCs,
but not for empty CS NCs [10], and it can be associated to the internalization of the NCs and the
stimulation of the TLR-7 receptor induced by the IMQ, as previously described for this immunostimulant
molecule [37]. The differences in cytokine concentration found between the CS and the INU/pArg NCs
could be due to differences in the internalization of the NCs or in the release of the IMQ. Low cytokine
levels induced by IMQ-loaded CS NCs in vitro were also described in a previous work [11].
The stability of the formulations at storage conditions (4 ◦C) was good for all the prototypes, or
the NCs before the addition of the antigen, in the case of CS NCs, but further lyophilization studies
should be carried out for a final prototype. In fact, the lyophilization of the INU/pArg prototypes
using 10% sucrose, as cryoprotectant, showed an efficient particle recovery after resuspension of the
lyophilized formulation in water.
CS and INU/pArg NCs showed a good cytocompatibility, although the toxicity was lower for CS
vs. INU/pArg NCs. These results were in line with previous findings regarding the higher toxicity
of pArg NCs than CS NCs [5,11]. On the other hand, INU NCs, without the pArg layer, showed
considerably lower toxicities [53,54]. In addition, the higher IMQ content in the INU/pArg NCs could
also be related with the increased toxicity [10].
Besides a higher cytocompatibility, CS NCs showed also a superior immunogenicity in vitro based
on the induction of cytokine and ROS release and complement activation, all of them mechanisms that
are related with an improved stimulation of the innate and adaptive immunity and associated efficacy
in vivo [5,26,31,32].
However, from the in vivo experiments, it can be concluded that INU:pArg:Ag NCs were the
only prototype able to induce specific IgA antibodies against the ESAT-6 antigen in mice immunized
three times intranasally with the NCs. Moreover, the INU:pArg:Ag and the CS:Ag NCs induced
high levels of IgG antibodies against the ESAT-6 and CFP-10 proteins, and IFN-γ and IL-17 release in
splenocytes re-stimulated with ESAT-6 or the fusion protein. In contrast, protection of the antigen in a
bilayer disposition (INU:Ag:pArg), despite increasing the stability of the NCs and the antigen loading
compared to the INU:pArg:Ag NCs, reduced significantly the immune response. The placement of
the antigen on the surface increased probably B-cell activation, as described previously [55,56]. Yet,
the polymeric composition played also a significant role because the CS:Ag NCs failed to induce
specific IgA antibodies although the antigen loading was also higher than for the INU:pArg:Ag.
Interestingly, the priming of the animals with the BCG vaccine (s.c. injected) only increased
or maintained the immune response induced by the CS:Ag NCs, while, in general, it decreased or
interfered with the response induced by the INU/pArg prototypes. In agreement with previous studies,
combining different routes of immunization can interfere on the mucosal immune response [57].
In general, priming at the mucosal level and boosting through a systemic route has shown to induce a
higher mucosal protection. However, this should be tested on individual prototypes because, in the
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case of the CS NCs, the priming with BCG did not interfere in the immune response induced by the NCs
alone, and even increased the cytokine release in re-stimulated splenocytes from vaccinated animals.
The studies of the immune response against the ECH fusion protein and the individual components
showed that ESAT-6 was a better antigen than CFP-10. The ESAT-6 protein was able to induce some
specific mucosal IgA production in animals vaccinated with the INU:pArg:Ag NCs, and IL-17 and
INF-γ release in splenocytes from animals immunized with the three vaccine prototypes after antigen
recall, while the CFP-10 protein induced minor or undetectable levels. Although Th17 and Th1 linages
are differently activated by ESAT-6, it has been shown in mice and human a developmental plasticity
of the Th17 cells that enable a shift from dominant IL-17 secretion to dominant IFN-γ expression
cells [58,59]. Hence, a combined immune response involving Th2 and either independent Th1 and
Th17 and/or Th1-Th17 cells was elicited by the polymeric NCs against the ESAT-6 antigen, based on
antibodies’ detection in animal serum and BAL, and cytokine release (IFN-γ and IL-17) in splenocytes
after the antigen recall experiment. In contrast, a clear Th2-type immune response was observed for
the CFP-10 antigen, based on antibody production.
The mucosal protection against ESAT-6, an Mtb-specific antigen that is not present in the BCG
vaccine, could help in the neutralization of the pathogen at the route of entrance. However, to achieve a
good immune protection for most of the population other antigens are needed. A recent computational
study on the immunogenicity potential of 10 antigens from Mtb predicted that Rv2608 could be the
most efficient one, based on the promiscuity of the epitopes to bind diverse human leukocyte antigen
(HLA) molecules that are frequent in the population of three high-TB-burden countries [60].
Besides, to avoid the inhibition of the immune response induced by the INU:pArg:Ag NCs in
animals previously immunized with the BCG vaccine, other vaccination regimes should be tested,
such as the priming through the i.n. route with the NCs and the boosting through the s.c. route with
the BCG vaccine.
5. Conclusions
Two different IMQ-loaded NCs, with a CS or an INU/pArg polymeric shell, were synthesized
for the development of an i.n. model vaccine containing a recombinant fusion protein (ECH) derived
from the ESAT-6 and CFP-10 antigen of Mtb. The vaccine containing INU:pArg:Ag NCs was the most
immunogenic prototype against the ECH fusion protein. Further optimization of the NCs to increase
the cellular response might provide an efficient antigen carrier for the development of new i.n. vaccines
to fight pathogens affecting the mucosa and airways.
Due to the interference of the BCG priming on the immune response, the use of INU:pArg:Ag NCs
for priming and, afterwards, a boost with the INU:pArg:Ag NCs or the conventional BCG vaccine (s.c.)
could improve the results observed for this prototype. In addition, antigen optimization should also
be considered to obtain a more efficient vaccine against Mtb because CFP-10 induced lower cellular
and humoral immune responses than the ESAT-6 protein.
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